Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Veronica Juan"'
Autor:
Xibei Dang, Lars Guelen, David Lutje Hulsik, Grigori Ermakov, Edward J. Hsieh, Joost Kreijtz, Judith Stammen-Vogelzangs, Imke Lodewijks, Astrid Bertens, Arne Bramer, Marco Guadagnoli, Alexis Nazabal, Andrea van Elsas, Thierry Fischmann, Veronica Juan, Amy Beebe, Maribel Beaumont, Hans van Eenennaam
Publikováno v:
mAbs, Vol 15, Iss 1 (2023)
ABSTRACTMonoclonal antibodies have become an important class of therapeutics in the last 30 years. Because the mechanism of action of therapeutic antibodies is intimately linked to their binding epitopes, identification of the epitope of an antibody
Externí odkaz:
https://doaj.org/article/23e30f5d2f8c4516bac906e80f9ad9d7
Autor:
David Prihoda, Jad Maamary, Andrew Waight, Veronica Juan, Laurence Fayadat-Dilman, Daniel Svozil, Danny A. Bitton
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Despite recent advances in transgenic animal models and display technologies, humanization of mouse sequences remains one of the main routes for therapeutic antibody development. Traditionally, humanization is manual, laborious, and requires expert k
Externí odkaz:
https://doaj.org/article/1cfab3de8e254294ae2cd13c6a106121
Autor:
David Rosen, Laurence Fayadat-Dilman, Yiwei Zhang, Konstantin Dobrenkov, Elliot Chartash, Richard Wnek, Smita Mauze, Hans van Eenennaam, Judith Stammen-Vogelzangs, Ying Yu, Marco Guadagnoli, Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Sean Troth, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Jannie Borst, Amy M Beebe
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 9 (2022)
Background Immune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of
Externí odkaz:
https://doaj.org/article/cc59fd0a12e04837b4168ce751ae8a2b
Autor:
Rachel L. Palte, Veronica Juan, Yacob Gomez-Llorente, Marc Andre Bailly, Kalyan Chakravarthy, Xun Chen, Daniel Cipriano, Laurence Fayadat-Dilman, Symon Gathiaka, Heiko Greb, Brian Hall, Mas Handa, Mark Hsieh, Esther Kofman, Heping Lin, J. Richard Miller, Nhung Nguyen, Jennifer O’Neil, Hussam Shaheen, Eric Sterner, Corey Strickland, Angie Sun, Shane Taremi, Giovanna Scapin
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-13 (2021)
Palte et al provide cryo-EM structures of five potent and inhibitory monoclonal antibodies bound to human Arginase 1, a T-cell modulating metalloenzyme and a cancer drug target. They provide structural insights that will aid in the evaluation of thes
Externí odkaz:
https://doaj.org/article/fbf41ee3e220482a9ea5fcab675f2be6
Autor:
Rachel L. Palte, Veronica Juan, Yacob Gomez-Llorente, Marc Andre Bailly, Kalyan Chakravarthy, Xun Chen, Daniel Cipriano, Ghassan N. Fayad, Laurence Fayadat-Dilman, Symon Gathiaka, Heiko Greb, Brian Hall, Mas Handa, Mark Hsieh, Esther Kofman, Heping Lin, J. Richard Miller, Nhung Nguyen, Jennifer O’Neil, Hussam Shaheen, Eric Sterner, Corey Strickland, Angie Sun, Shane Taremi, Giovanna Scapin
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-2 (2021)
Externí odkaz:
https://doaj.org/article/15828ecf3c6a4e49a73581c4631d3a3d
Autor:
Pin-Kuang Lai, Gaurav Ghag, Yao Yu, Veronica Juan, Laurence Fayadat-Dilman, Bernhardt L. Trout
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Human/humanized IgG4 antibodies have reduced effector function relative to IgG1 antibodies, which is desirable for certain therapeutic purposes. However, the developability and biophysical properties for IgG4 antibodies are not well understood. This
Externí odkaz:
https://doaj.org/article/944b83f5f34449e7a67f388df2b8013b
Autor:
Marc Bailly, Carl Mieczkowski, Veronica Juan, Essam Metwally, Daniela Tomazela, Jeanne Baker, Makiko Uchida, Ester Kofman, Fahimeh Raoufi, Soha Motlagh, Yao Yu, Jihea Park, Smita Raghava, John Welsh, Michael Rauscher, Gopalan Raghunathan, Mark Hsieh, Yi-Ling Chen, Hang Thu Nguyen, Nhung Nguyen, Dan Cipriano, Laurence Fayadat-Dilman
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Monoclonal antibodies play an increasingly important role for the development of new drugs across multiple therapy areas. The term ‘developability’ encompasses the feasibility of molecules to successfully progress from discovery to development vi
Externí odkaz:
https://doaj.org/article/adb0a7cc163a47868054a9dee9dd053c
Autor:
Jad Maamary, Andrew Waight, Danny A. Bitton, David Prihoda, Daniel Svozil, Laurence Fayadat-Dilman, Veronica Juan
Publikováno v:
mAbs, Vol 14, Iss 1 (2022)
Despite recent advances in transgenic animal models and display technologies, humanization of mouse sequences remains the primary route for therapeutic antibody development. Traditionally, humanization is manual, laborious, and requires expert knowle
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b696d30d0cf1d140a497338b560e17
https://doi.org/10.1080/19420862.2021.2020203
https://doi.org/10.1080/19420862.2021.2020203
Autor:
Philip E. Brandish, Anthony Palmieri, Gulesi Ayanoglu, Jeanne Baker, Raphael Bueno, Alan Byford, Michael Caniga, Craig Chappell, Holly Cherwinski, Daniel J. Cua, Xiaoyan Du, Laurence Fayadat-Dilman, Brian E. Hall, Hassan Issafras, Barbara Joyce-Shaikh, Veronica Juan, Rachel D. Levy, Andrey Loboda, Jared Lunceford, Carl Mieczkowski, Michael Meehl, Yujie Qu, Michael Rosenzweig, Latika Singh, Peter Stivers, Peter J. Tramontozzi, Kimberly Vermilya, Karin Vroom, Douglas C. Wilson, Chungsheng Zhang, Jie Zhang-Hoover
Tumor myeloid suppressor cells impede response to T cell checkpoint immunotherapy. Immunoglobulin-like transcript 3 (ILT3, gene name, LILRB4) expressed on dendritic cells (DCs) promotes antigen-specific tolerance. Circulating monocytic MDSCs that exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::72b5e16ef1b15fd1e3d724e4d5c0bdd7
https://doi.org/10.1101/2021.12.18.472552
https://doi.org/10.1101/2021.12.18.472552
Autor:
Lars Guelen, Thierry O Fischmann, Jerelyn Wong, Smita Mauze, Marco Guadagnoli, Nikolina Bąbała, Jozef Wagenaars, Veronica Juan, David Rosen, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Judith Stammen-Vogelzangs, Ying Yu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Yiwei Zhang, Richard Wnek, Sean Troth, Elliot Chartash, Konstantin Dobrenkov, Svetlana Sadekova, Andrea van Elsas, Jason K Cheung, Laurence Fayadat-Dilman, Jannie Borst, Amy M Beebe, Hans Van Eenennaam
Publikováno v:
Journal for ImmunoTherapy of Cancer, 10(9). BMJ PUBLISHING GROUP
BackgroundImmune checkpoint inhibitors (ICI) have radically changed cancer therapy, but most patients with cancer are unresponsive or relapse after treatment. MK-5890 is a CD27 agonist antibody intended to complement ICI therapy. CD27 is a member of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e2a5657834d447f836b811d356fb97
https://doi.org/10.1136/jitc-2022-005049
https://doi.org/10.1136/jitc-2022-005049